Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

13,644 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Four versus six cycles of platinum-based chemotherapy for advanced Urothelial carcinoma in the era of immune checkpoint inhibitors: A retrospective cohort study (FOCUS, KCSG-GU23-08).
Park K, Kim EJ, Kim JY, Kim H, Park I, Park JH, Sohn BS, Lee HJ, Jo J, Huh SJ, Lee JL. Park K, et al. Among authors: lee hj, lee jl. Curr Probl Cancer. 2024 Dec;53:101149. doi: 10.1016/j.currproblcancer.2024.101149. Epub 2024 Sep 22. Curr Probl Cancer. 2024. PMID: 39312854
Clinical Characteristics of Clear Cell Ovarian Cancer: A Retrospective Multicenter Experience of 308 Patients in South Korea.
Lee HY, Hong JH, Byun JH, Kim HJ, Baek SK, Kim JY, Kim KH, Yun J, Kim JA, Park K, Lee HJ, Lee JL, Won YW, Kim IH, Bae WK, Park KH, Sun DS, Lee S, Lee MY, Lee GJ, Hong SH, Jung YH, An HJ. Lee HY, et al. Among authors: lee my, lee s, lee gj, lee hj, lee jl. Cancer Res Treat. 2020 Jan;52(1):277-283. doi: 10.4143/crt.2019.292. Epub 2019 Jul 12. Cancer Res Treat. 2020. PMID: 31319640 Free PMC article.
Comparative effectiveness of palliative chemotherapy versus neoadjuvant chemotherapy followed by radical cystectomy versus cystectomy followed by adjuvant chemotherapy versus cystectomy for regional node-positive bladder cancer: A retrospective analysis: KCSG GU 17-03.
Bae WK, Lee HJ, Park SH, Kim JH, Kim HJ, Maeng CH, Park I, Sohn BS, Kim JA, Lee KH, Lim DH, Chang H, Kim SM, Kim HY, Song H, Lim S, Byun JH, Jung HA. Bae WK, et al. Among authors: lee kh, lee hj. Cancer Med. 2019 Sep;8(12):5431-5437. doi: 10.1002/cam4.2446. Epub 2019 Jul 29. Cancer Med. 2019. PMID: 31353788 Free PMC article.
Gemcitabine plus carboplatin versus gemcitabine plus oxaliplatin in cisplatin-unfit patients with advanced urothelial carcinoma: a randomised phase II study (COACH, KCSG GU10-16).
Park I, Kim BS, Lim HY, Kim HJ, Lee HJ, Choi YJ, Park KH, Lee KH, Yoon S, Hong B, Hong JH, Ahn H, Lee JL. Park I, et al. Among authors: lee kh, lee hj, lee jl. Eur J Cancer. 2020 Mar;127:183-190. doi: 10.1016/j.ejca.2019.08.034. Epub 2019 Oct 24. Eur J Cancer. 2020. PMID: 31668839 Clinical Trial.
2020 Korean guidelines for the management of metastatic prostate cancer.
Kim IH, Shin SJ, Kang BW, Kang J, Kim D, Kim M, Kim JY, Kim CK, Kim HJ, Maeng CH, Park K, Park I, Bae WK, Sohn BS, Lee MY, Lee JL, Lee J, Lim ST, Lim JH, Chang H, Jung JY, Choi YJ, Kim YS, Cho J, Joung JY, Park SH, Lee HJ. Kim IH, et al. Among authors: lee j, lee my, lee jl, lee hj. Korean J Intern Med. 2021 May;36(3):491-514. doi: 10.3904/kjim.2020.213. Epub 2021 Feb 10. Korean J Intern Med. 2021. PMID: 33561334 Free PMC article. Review.
Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study.
Siefker-Radtke AO, Necchi A, Park SH, García-Donas J, Huddart RA, Burgess EF, Fleming MT, Rezazadeh Kalebasty A, Mellado B, Varlamov S, Joshi M, Duran I, Tagawa ST, Zakharia Y, Akapame S, Santiago-Walker AE, Monga M, O'Hagan A, Loriot Y; BLC2001 Study Group. Siefker-Radtke AO, et al. Lancet Oncol. 2022 Feb;23(2):248-258. doi: 10.1016/S1470-2045(21)00660-4. Epub 2022 Jan 11. Lancet Oncol. 2022. PMID: 35030333 Clinical Trial.
13,644 results
You have reached the last available page of results. Please see the User Guide for more information.